@article{b19de3d879a3404f9b2d6ee6842f379e,
title = "Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases",
abstract = "Lung involvement in connective tissue diseases is associated with substantial morbidity and mortality, most commonly in the form of interstitial lung disease, and can occur in any of these disorders. Patterns of interstitial lung disease in patients with connective tissue disease are similar to those seen in idiopathic interstitial pneumonias, such as idiopathic pulmonary fibrosis. It may be difficult to distinguish between the 2 ailments, particularly when interstitial lung disease presents before extrapulmonary manifestations of the underlying connective tissue disease. There are important clinical implications in achieving this distinction. Given the complexities inherent in the management of these patients, a multidisciplinary evaluation is needed to optimize the diagnostic process and management strategies. The aim of this article was to summarize an approach to diagnosis and management based on the opinion of experts on this topic.",
author = "Isabel Mira-Avendano and Andy Abril and Burger, {Charles D.} and Dellaripa, {Paul F.} and Aryeh Fischer and Gotway, {Michael B.} and Lee, {Augustine S.} and Lee, {Joyce S.} and Matteson, {Eric L.} and Yi, {Eunhee S.} and Ryu, {Jay H.}",
note = "Funding Information: Potential Competing Interests: Dr Burger has received unrestricted research grants from Actelion Pharmaceuticals Inc and United Therapeutics. Dr Dellaripa received payment for writing or reviewing the manuscript from UpToDate, has participated in research projects in conjunction with Genentech, and receives royalties from UpToDate and Springer Publications. Dr Fischer has served as a consultant to Boehringer Ingelheim and F Hoffman La Roche, and has received grants from Boehringer Ingelheim and Corbus Pharmaceuticals. Dr Joyce S. Lee has received grants from the National Institutes of Health; has served on the speakers' bureau of XXX; has received royalties from XXX; and has been a 1-time advisory board member for Celgene, Genentech, and Boehringer Ingelheim. Dr Matteson has served as a board member for Janssen and as a consultant for Amgen; has received grants from Pfizer, GlaxoSmithKline, and Sun Pharmaceutical Industries Ltd; and receives royalties from UpToDate. The rest of the authors report no competing interests. Funding Information: Potential Competing Interests: Dr Burger has received unrestricted research grants from Actelion Pharmaceuticals Inc and United Therapeutics. Dr Dellaripa received payment for writing or reviewing the manuscript from UpToDate, has participated in research projects in conjunction with Genentech, and receives royalties from UpToDate and Springer Publications. Dr Fischer has served as a consultant to Boehringer Ingelheim and F Hoffman La Roche, and has received grants from Boehringer Ingelheim and Corbus Pharmaceuticals. Dr Joyce S. Lee has received grants from the National Institutes of Health and has been a 1-time advisory board member for Celgene, Genentech, and Boehringer Ingelheim. Dr Matteson has served as a board member for Janssen and as a consultant for Amgen; has received grants from Pfizer, GlaxoSmithKline, and Sun Pharmaceutical Industries Ltd; and receives royalties from UpToDate. The rest of the authors report no competing interests. Funding Information: Potential Competing Interests: Dr Burger has received unrestricted research grants from Actelion Pharmaceuticals Inc and United Therapeutics . Dr Dellaripa received payment for writing or reviewing the manuscript from UpToDate, has participated in research projects in conjunction with Genentech, and receives royalties from UpToDate and Springer Publications. Dr Fischer has served as a consultant to Boehringer Ingelheim and F Hoffman La Roche, and has received grants from Boehringer Ingelheim and Corbus Pharmaceuticals . Dr Joyce S. Lee has received grants from the National Institutes of Health ; has served on the speakers' bureau of XXX; has received royalties from XXX; and has been a 1-time advisory board member for Celgene, Genentech, and Boehringer Ingelheim. Dr Matteson has served as a board member for Janssen and as a consultant for Amgen; has received grants from Pfizer , GlaxoSmithKline , and Sun Pharmaceutical Industries Ltd ; and receives royalties from UpToDate. The rest of the authors report no competing interests. Publisher Copyright: {\textcopyright} 2018",
year = "2019",
month = feb,
doi = "10.1016/j.mayocp.2018.09.002",
language = "English (US)",
volume = "94",
pages = "309--325",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",
}